Zepbound (Tirzepatide) Side Effects: Trial Rates

If nausea is affecting food or fluids, our GLP-1 nausea guide explains what to report and what follow-up support to ask about.

Tirzepatide's weight-loss results get most of the headlines; the side-effect profile that comes with them gets less attention than it should. This guide sticks to what the actual trials and a dedicated adverse-event review report — no forum anecdotes, no invented percentages.

What are the most common Zepbound side effects?

Across tirzepatide's own pivotal obesity trial, gastrointestinal side effects were the most commonly reported adverse events, mainly nausea, diarrhea, constipation and vomiting, generally described as mild to moderate and concentrated during dose escalation¹. A dedicated review of adverse events tied to tirzepatide reaches the same conclusion: GI effects are the leading category, and they tend to cluster around dose increases rather than persisting flat across treatment². That timing matters practically — the FDA-cleared titration schedule exists specifically to reduce how hard the GI system gets hit at any one step.

How common is each Zepbound side effect?

The Zepbound label pools two placebo-controlled weight-loss trials and lists every reaction that showed up in at least 2% of people and more often than on placebo. These are the rates by maintenance dose⁴:

Taken together, some kind of stomach or gut reaction showed up in 56% of people at every Zepbound dose, against 30% on placebo⁴. Constipation is the one effect that ran lower at the higher doses in this pool; nausea, diarrhea and vomiting all rose with the dose.

How many people stop Zepbound because of side effects?

In tirzepatide's pivotal 72-week obesity trial, a meaningful share of participants on the medication stopped it because of an adverse event, at a rate higher than on placebo, and GI-related effects were the most common reason cited¹. The label's pooled figures put it at 4.8%, 6.3% and 6.7% on the 5 mg, 10 mg and 15 mg doses, against 3.4% on placebo, with most of those stops in the first few months⁴. That is a real number, not zero, and it is also not most people: the majority of trial participants stayed on treatment through the full study period. If you are the person for whom side effects do not settle after a few weeks, discontinuation was a genuine outcome for some trial participants, not an outlier no one experienced.

Head-to-head against semaglutide

A direct randomized comparison of tirzepatide against semaglutide for obesity found broadly comparable safety and tolerability profiles between the two, both dominated by the same GI-effect category, on top of tirzepatide's edge in average weight loss³. In other words, moving to tirzepatide for better results does not appear to trade away safety for efficacy relative to semaglutide — the side-effect shape is similar; what differs is more the intensity felt during titration for a given individual, which trial-level averages can't predict for any one reader. Our semaglutide vs tirzepatide value comparison covers the efficacy and price side of this same trade.

What the label itself flags beyond GI effects

Beyond the GI-effect majority, tirzepatide's FDA labeling carries warnings clinicians screen for before prescribing, including thyroid C-cell tumor risk seen in rodent studies (unconfirmed in humans, but the reason for a personal or family medical-thyroid-cancer screening question on intake), acute pancreatitis, gallbladder problems, and hypoglycemia risk when combined with insulin or a sulfonylurea. What the largest RCT meta-analyses and real-world cohorts actually show for those last two — gallbladder risk confirmed, pancreatitis risk more nuanced than the label alone suggests — is covered in full in GLP-1s, pancreatitis and gallbladder risk. This is exactly why real clinical review before prescribing is a scored factor in our methodology rather than a checkbox — a provider that skips it is skipping the point where these risks actually get screened. A few more areas worth knowing the real evidence on: hair loss on a GLP-1, what actually interacts with alcohol and other drugs, and — since tirzepatide's own label carries a second, independent FDA indication most people don't know about — what Zepbound's sleep apnea trial actually found.

What this means before you buy

Expect some GI discomfort during the first several weeks, expect it to ease as you plateau on a dose, and expect that a real minority of people stop because it doesn't ease enough for them. None of that is a reason to avoid the medication outright — it is a reason to titrate on the labeled schedule, use a provider with actual clinician oversight rather than an auto-approved intake, and treat tirzepatide (compounded or brand) as a medical decision, not a subscription purchase. If you're comparing tirzepatide sources, our compounded tirzepatide explainer and what Zepbound actually costs cover the brand-vs-compounded distinction and current pricing; if semaglutide's side-effect profile is the other half of your decision, see semaglutide side effects. Two specific concerns deserve their own deeper look: whether tirzepatide or semaglutide actually causes fatigue, and what the boxed cancer warning is actually based on. The trial sources behind every figure above are collected in our research library. Not medical advice — see our medical disclaimer and talk to a clinician about your own history.